Li-kun Chen

This phase 2 trial tests a combination of two drugs, Sacituzumab tirumotecan and bevacizumab, in 50 people with a specific type of lung cancer (EGFR-mutant nonsquamous NSCLC) that has spread to the brain and no longer responds to standard targeted therapy. The goal is to see if t…